Listar por Categoría
Mostrando ítems 81-100 de 203
-
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Importance: WHO has made the assessment that coronavirus disease 2019 (COVID-19) can be characterized as a pandemic. But there is no effective antiviral drug for COVID-19 so far. Objective: To compare the efficacy and ... -
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
(2020-09-24)Background: The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that ... -
The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro
(2020-04-03)Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved ... -
Heparin therapy improving hypoxia in COVID-19 patients - a case series
(2020-04-30)INTRODUCTION: Elevated D-dimer is a predictor of severity and mortality in COVID-19 patients and heparin use during in-hospital stay has been associated with decreased mortality. COVID-19 patient autopsies have revealed ... -
High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission
(2020-06-15)Purpose: We conducted two World Health Organization-commissioned reviews to inform use of high-flow nasal cannula (HFNC) in patients with coronavirus disease (COVID-19). We synthesized the evidence regarding efficacy and ... -
How Big Data and Artificial Intelligence Can Help Better Manage the COVID-19 Pandemic
(2020-05-02)SARS-CoV2 is a novel coronavirus, responsible for the COVID-19 pandemic declared by the World Health Organization. Thanks to the latest advancements in the field of molecular and computational techniques and information ... -
Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients
(2020-05-08)Background: COVID-19 has rapidly emerged as a pandemic infection that has caused significant mortality and economic losses. Potential therapies and means of prophylaxis against COVID-19 are urgently needed to combat this ... -
Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19
(2020-05-01)Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high mortality. The most urgent thing is to find effective treatments. Objective: To determine whether hydroxychloroquine application ... -
Hydroxychloroquine in COVID-19: A systematic review and meta-analysis
(2020-05-20)Abstract Background Hydroxychloroquine is being administered among patients with COVID19 infection in many healthcare systems across the world considering its in vitro effect against the SARS CoV 2 virus. In spite of several ... -
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019
(2020-05-14)Objective To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19). Design Multicentre, open label, randomised ... -
Hydroxychloroquine safety: A meta-analysis of randomized controlled trials
(2020-07-06)Background: Hydroxychloroquine (HCQ) is currently being examined for COVID-19. No previous meta-analysis has evaluated its side effects versus placebo. We conducted this meta-analysis to compare the safety of HCQ versus ... -
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
(2020-07-03)BACKGROUND Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. METHODS We conducted a ... -
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
(2020-05-05)We performed a meta-analysis to determine safety and efficacy of corticosteroids in SARS-CoV-2, SARS-CoV, and MERS-CoV infections. We searched PubMed, Web of Science, Medline, WanFang Chinese database, and ZhiWang Chinese ... -
Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis
(2020-11-05)Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused significant health and economic havoc around the globe. One of the early agents targeted for repurposing ... -
Impacts of remdesivir on dynamics and efficacy stratified by the severity of COVID- 19: a simulated two-arm controlled study
(2020-05-22)Background: The impact of remdesivir on length of stay of hospitalization, high-risk state, and death stratified by the severity of COVID-19 at enrollment is controversial. Methods: We applied a simulated two-arm controlled ... -
In vitro testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows synergistic effect
(2020-03)Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term ... -
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine
(2020-05-06)Urgent action is needed to fight the ongoing COVID-19 pandemic by reducing the number of infected people along with the infection contagiousness and severity. Chlorpromazine (CPZ), the prototype of typical antipsychotics ... -
Intravenous Ascorbic Acid (IVAA) for COVID-19: supportive treatment in hospitalized COVID-19 patients: based on use in China and US settings
(2020-03-23)Intravenous ascorbic acid (IVAA) is a well-known intervention in medicine, which currently is rarely used in US hospitals. Due to the unusual and extreme clinical demands of hospitalized COVID-19 patients, IVAA has been ... -
Investigational COVID-19 Convalescent Plasma - Emergency INDs
(2020-03-24)The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States from public health threats including the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to doing ... -
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
(2020)In December 2019, a cluster of patients with pneumonia of unknown cause was reported in Wuhan (China). After analysis of respiratory samples, scientists isolated a new virus, named severe acute respiratory syndrome coronavirus ...